Patents Assigned to Adamas Pharma, LLC
-
Patent number: 12233033Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.Type: GrantFiled: June 4, 2021Date of Patent: February 25, 2025Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
-
Patent number: 11903908Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: November 3, 2020Date of Patent: February 20, 2024Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
-
Patent number: 11197835Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: December 26, 2019Date of Patent: December 14, 2021Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 11077073Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.Type: GrantFiled: May 10, 2019Date of Patent: August 3, 2021Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
-
Patent number: 11065213Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.Type: GrantFiled: November 7, 2019Date of Patent: July 20, 2021Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Sangita Ghosh, Natalie McClure
-
Patent number: 10646456Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: November 13, 2018Date of Patent: May 12, 2020Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
-
Patent number: 10154971Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: June 17, 2014Date of Patent: December 18, 2018Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
-
Publication number: 20180263928Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: ApplicationFiled: May 21, 2018Publication date: September 20, 2018Applicant: Adamas Pharma, LLCInventors: Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
-
Patent number: 9877933Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: February 9, 2017Date of Patent: January 30, 2018Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 9867792Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: February 9, 2017Date of Patent: January 16, 2018Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 9867793Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: February 10, 2017Date of Patent: January 16, 2018Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
-
Patent number: 9867791Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.Type: GrantFiled: February 9, 2017Date of Patent: January 16, 2018Assignee: Adamas Pharma, LLCInventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare